Chips, Earnings, and Big Exec Bets Dominate Monday
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Micron in the Spotlight
Micron is the name everyone is watching this week. The memory chipmaker reports Q3 results on Wednesday. It has rallied 200% from its April low. Options positioning is heavy across 23 active expiry dates. Short interest is just 3.3% of free float. That tells you bulls are firmly in charge. AI server demand is the key metric to watch.
Bears Pile Into Chips and Semis
Short sellers are making bold moves in the chip space. Wolfspeed leads all stocks with a short interest of 103% of free float — up 8 points in a week. That means shorts exceed the entire free float. Cerebras Systems hit 32.4% SI % FF, up nearly 7 points since its IPO. NVIDIA itself carries only 1.3% short interest, but its $5.1 trillion market cap makes any shift significant.
Analysts Split on Tech and Materials
Accenture took the hardest analyst hit. Average target fell $10.51 to $197.65. Fifteen analysts now carry a sell rating. Albemarle went the other way. The lithium miner's target crept higher. With 9.1% short interest, a rising target could pressure bears. Eli Lilly received another price target bump to $1,218.72.
Insider Split: Buy vs. Sell
Summit Therapeutics CEO Robert Duggan bought $50M of SMMT stock — a strong personal conviction bet. The Walton Family Trust offset that optimism. It filed this week disclosing a $467M sale of WMT shares on June 16. Applied Materials CEO Gary Dickerson also filed $49M in sales near multi-year highs.
Carnival and FedEx also report this week, giving markets a read on consumer travel and logistics demand.
Stocks in this article
How this article was generated
- Generated
- 21 Jun 2026, 04:50
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.